Submit your email to push it up the queue
Maquet Cardiovascular, LLC, a prominent player in the medical device industry, is headquartered in the United States. Founded in 1838, the company has established itself as a leader in cardiovascular solutions, focusing on innovative technologies for cardiac surgery and critical care. With a strong presence in North America and Europe, Maquet Cardiovascular is renowned for its advanced products, including heart-lung machines and surgical instruments, which are designed to enhance patient outcomes and streamline surgical procedures. The company’s commitment to quality and innovation has earned it a significant market position, with notable achievements in developing cutting-edge technologies that improve surgical efficiency. Maquet Cardiovascular continues to set industry standards, making it a trusted partner for healthcare professionals worldwide.
How does Maquet Cardiovascular, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Maquet Cardiovascular, LLC's score of 85 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Maquet Cardiovascular, LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Getinge AB (publ), which influences its climate commitments and initiatives. As part of its corporate family relationship, Maquet Cardiovascular inherits climate-related targets and initiatives from Getinge AB. This includes commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific reduction targets for Maquet Cardiovascular are not detailed. The absence of direct emissions data suggests that Maquet Cardiovascular is in the process of developing its own climate strategy, potentially aligning with the broader goals set by Getinge AB. The company is expected to contribute to the overarching sustainability efforts of its parent organisation, which may include initiatives aimed at reducing Scope 1, 2, and 3 emissions. In summary, while specific emissions data for Maquet Cardiovascular is not available, the company is positioned within a framework of climate commitments inherited from Getinge AB, indicating a commitment to sustainability and carbon reduction in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
Scope 1 | 6,661,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 12,643,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 8,238,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Maquet Cardiovascular, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.